



**IOL CHEMICALS AND PHARMACEUTICALS LIMITED**

16<sup>th</sup> May 2025  
IOLCP/CGC/2025

**National Stock Exchange of India Ltd**

Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E)  
Mumbai - 400 051

**Security Symbol: IOLCP**

**BSE Limited**

Phiroze Jeejeebhoy Towers,  
Dalal Street  
Mumbai – 400 001

**Security Code: 524164**

**Subject: Press Release – Financial Results for the quarter and year ended 31<sup>st</sup> March 2025**

Dear Sir,

Pursuant to Regulation 30 read with Schedule III of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015, please find enclosed a Press Release dated 16<sup>th</sup> May 2025 with respect to financial results for the quarter and year ended 31<sup>st</sup> March 2025.

Hope you will find the same in order.

Thanking You,

Yours faithfully,  
for IOL Chemicals and Pharmaceuticals Limited

Abhay Raj Singh  
Sr. Vice President & Company Secretary



IOL Chemicals And Pharmaceuticals Limited



## IOL Chemicals & Pharmaceuticals Limited Delivers Strong Q4 Performance

**Achieves 17% EBITDA and 12% PAT Growth Year-on-Year Amidst Industry Headwinds**

**Ludhiana, 16<sup>th</sup> May 2025:** IOL Chemicals & Pharmaceuticals Ltd., one of the leading manufacturers of Pharmaceuticals & Specialty Chemicals announced its audited financial results for the quarter and year ended 31<sup>st</sup> March 2025.

### Q4 FY25 Financial Performance Snapshot

(Standalone)

<b>Revenue from Operations</b> <b>₹ 527.8 Cr</b>  <b>4.7%</b>	<b>EBITDA</b> <b>₹ 67.5 Cr</b>  <b>17.1%</b>	<b>Profit After Tax</b> <b>₹ 31.6 Cr</b>  <b>12.2%</b>
--	---	---


### Key Standalone Financial Highlights

Particulars (₹ Cr)	Q4 FY25	Q4 FY24	Y-o-Y	FY25	FY24
Revenue from Operations	527.8	503.9	4.7%	2,079.2	2,132.8
Gross Profit	186.5	188.9	-1.3%	709.8	765.9
Gross Margin (%)	35.0%	36.9%	-190 bps	33.8%	35.4%
EBITDA	67.5	57.6	17.1%	224.6	261.6
EBITDA Margin (%)	12.7%	11.3%	+141 bps	10.7%	12.1%
Profit After Tax	31.6	28.2	12.2%	101.0	135.4
PAT Margin (%)	5.9%	5.5%	+43 bps	4.8%	6.3%
Cash Profit After Tax*	56.4	49.2	14.6%	185.1	208.5

\* Profit Before Tax + Depreciation- Current Tax

### Segment Highlights

(In ₹ Cr)





### Q4 FY25 Operational Highlights

- Successfully Commissioned **Unit-11 for Paracetamol** at the Barnala facility with an annual capacity of 10,800 MTPA; ₹155.51 crore investment fully funded through internal accruals
- Expanded **Clopidogrel Bisulphate** capacity from 180 MTPA to 240 MTPA at Unit-5 with an investment of ₹7.87 crore, financed through internal funds
- Received **EDQM Certification of Suitability (CEPs)** for **Mesalazine** and **Quetiapine Fumarate**, enabling exports to Europe and other CEP-compliant markets
- Secured approval from **China's National Medical Products Administration (NMPA)** to export **Ibuprofen**, marking entry into one of the world's largest pharmaceutical markets
- Acquired **101 acres** along the Chandigarh-Bathinda Highway for future expansion; regulatory and environmental clearances currently in progress.

### Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said,

*"In Q4FY25, we delivered sustainable performance, with the Ibuprofen segment showing improved traction despite intense competition and continued pricing pressure in global markets. A key highlight was the successful commissioning of our fully backward-integrated Paracetamol production unit, with an installed capacity of 10,800 MTPA. This has tripled our Paracetamol capacity, enabling us to strengthen our non-Ibuprofen portfolio, particularly in high-demand, fast-moving therapeutic categories. Notably, pricing and demand across our broader API basket remained stable. However the chemicals segment delivered stable performance despite muted volumes, as enhanced operational efficiencies across key units contributed to a notable improvement in EBIT.*



*FY25 was marked by strategic consolidation and investments focused on capacity enhancement, improved utilization, cost control, and regulatory expansion. Our strong backward integration model continues to drive cost control, supply reliability, and operating leverage. We remain committed to strengthening our portfolio, driving operational excellence, and expanding our market reach to create sustained value."*

### About IOL Chemicals & Pharmaceuticals Ltd.

IOL Chemicals and Pharmaceuticals Ltd. (IOLCP), established in 1986 and headquartered in Ludhiana, Punjab, is a leading Indian manufacturer of Active Pharmaceutical Ingredients (APIs) and specialty chemicals. It is the world's largest producer of Ibuprofen with a 30% global market share, the second-largest global producer of Iso Butyl Benzene (IBB), and a key manufacturer of Ethyl Acetate in India. IOLCP's API portfolio spans key therapeutic areas such as pain management, anti-convulsants, anti-diabetics, and cardiovascular care. With exports to over 80 countries—including the USA, UK, China, and Germany—and strong regulatory approvals, the company is well-positioned for global growth. Its backward-integrated operations and ongoing capacity expansion support long-term scalability and resilience.



### Contact Details

IOL Chemicals & Pharmaceuticals Ltd.		Investor Relations: MUFG Intime India Pvt. Ltd.	
			
CIN: L24116PB1986PLC007030		Ms. Prachi Ambre +918355985370/ <a href="mailto:prachi.ambre@in.mpms.mufig.com">prachi.ambre@in.mpms.mufig.com</a>	
Mr. Abhay Raj Singh Sr. VP & Company Secretary <a href="mailto:investor@iolcp.com">investor@iolcp.com</a>		Mr. Irfan Raeen +91 9773778669/ <a href="mailto:irfan.raeen@in.mpms.mufig.com">irfan.raeen@in.mpms.mufig.com</a>	

### Safe Harbor Statement

Any forward-looking statements about expected future events, financial and operating results of the Company are based on certain assumptions which the Company does not guarantee the fulfilment of. These statements are subject to risks and uncertainties. Actual results might differ substantially or materially from those expressed or implied. Important developments that could affect the Company's operations include a downtrend in the industry, global or domestic or both, significant changes in political and economic environment in India or key markets abroad, tax laws, litigation, labour relations, exchange rate fluctuations, technological changes, investment and business income, cash flow projections, interest, and other costs. The Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof.